318 related articles for article (PubMed ID: 27263935)
1. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Helfferich J; Nijmeijer R; Brouwer OF; Boon M; Fock A; Hoving EW; Meijer L; den Dunnen WF; de Bont ES
Crit Rev Oncol Hematol; 2016 Aug; 104():30-41. PubMed ID: 27263935
[TBL] [Abstract][Full Text] [Related]
2. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
3. [Developmental manifestation in children with neurofibromatosis type 1].
Cohen R; Shuper A
Harefuah; 2010 Jan; 149(1):49-52, 61. PubMed ID: 20422842
[TBL] [Abstract][Full Text] [Related]
4. Gliomas in patients with neurofibromatosis type 1.
Albers AC; Gutmann DH
Expert Rev Neurother; 2009 Apr; 9(4):535-9. PubMed ID: 19344304
[TBL] [Abstract][Full Text] [Related]
5. [Neurofibromatosis von Recklinghausen type 1 (NF1) - clinical picture and molecular-genetics diagnostic].
Petrák B; Bendová Š; Lisý J; Kraus J; Zatrapa T; Glombová M; Zámečník J
Cesk Patol; 2015; 51(1):34-40. PubMed ID: 25671360
[TBL] [Abstract][Full Text] [Related]
6. Atypical hematologic and renal manifestations in neurofibromatosis type I: coincidence or pathophysiological link?
Van-Gils J; Harambat J; Jubert C; Vidaud D; Llanas B; Perel Y; Lacombe D; Goizet C
Eur J Med Genet; 2014; 57(11-12):639-42. PubMed ID: 25234363
[TBL] [Abstract][Full Text] [Related]
7. Giant café-au-lait macule in neurofibromatosis 1: a type 2 segmental manifestation of neurofibromatosis 1?
Yang CC; Happle R; Chao SC; Yu-Yun Lee J; Chen W
J Am Acad Dermatol; 2008 Mar; 58(3):493-7. PubMed ID: 18280349
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas.
Byrne S; Connor S; Lascelles K; Siddiqui A; Hargrave D; Ferner RE
J Neurooncol; 2017 Jul; 133(3):609-614. PubMed ID: 28593402
[TBL] [Abstract][Full Text] [Related]
9. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1.
Leonard JR; Perry A; Rubin JB; King AA; Chicoine MR; Gutmann DH
Neurology; 2006 Oct; 67(8):1509-12. PubMed ID: 17060590
[TBL] [Abstract][Full Text] [Related]
10. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.
Strowd RE; Rodriguez FJ; McLendon RE; Vredenburgh JJ; Chance AB; Jallo G; Olivi A; Ahn ES; Blakeley JO
Am J Med Genet A; 2016 Jun; 170(6):1455-61. PubMed ID: 26992069
[TBL] [Abstract][Full Text] [Related]
11. Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type I.
Moramarco A; Mallone F; Sacchetti M; Lucchino L; Miraglia E; Roberti V; Lambiase A; Giustini S
Orphanet J Rare Dis; 2021 Mar; 16(1):147. PubMed ID: 33757576
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
13. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
14. [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome].
Wimmer K
Wien Med Wochenschr; 2005 Jun; 155(11-12):273-80. PubMed ID: 16035388
[TBL] [Abstract][Full Text] [Related]
15. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
16. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
18. [A novel neurocutaneous syndrome: Legius syndrome. A case report].
Cemeli-Cano M; Peña-Segura JL; Fernando-Martínez R; Izquierdo-Álvarez S; Monge-Galindo L; López-Pisón J
Rev Neurol; 2014 Sep; 59(5):209-12. PubMed ID: 25156025
[TBL] [Abstract][Full Text] [Related]
19. [Neurofibromatosis type 1 and associated clinical abnormalities in 27 children].
Syrbe S; Eberle K; Strenge S; Bernhard MK; Herbertz S; Bierbach U; Hirsch W; Froster UG; Kiess W; Merkenschlager A
Klin Padiatr; 2007; 219(6):326-32. PubMed ID: 18183640
[TBL] [Abstract][Full Text] [Related]
20. [Clinical diagnosis of neurofibromatosis type 1].
Wolkenstein P; Zeller J
Presse Med; 1999 Dec; 28(39):2174-80. PubMed ID: 10629698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
